Clinical Trial Update: Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ipilimumab and nivolumab followed by adjuvant nivolumab in locally advanced or limited metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: European Institute of Oncology | Conditions: Melanoma | Phase 2 | Status: UNKNOWN